Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant gender » significant concern (Expand Search), significant burden (Expand Search)
significant event » significant effect (Expand Search), significant level (Expand Search), significant effects (Expand Search)
Showing 1 - 20 results of 28 for search '(( significant decrease decrease ) OR ( ((significant event) OR (significant gender)) decrease ))~', query time: 0.53s Refine Results
  1. 1
    Study-related adverse events.

    Study-related adverse events. by Benjamin R. Lewis (22279166)

    Published 2025
    “…In a linear mixed model analysis (LMM), the MBSR + PAP arm evidenced a significantly larger decrease in QIDS-SR-16 score than the MBSR-only arm from baseline to 2-weeks post-intervention (between-groups effect = 4.6, 95% CI [1.51, 7.70]; <i>p</i> = 0.008). …”
    Save to List
    Saved in:
  2. 2
    Study flow chart.

    Study flow chart. by Benjamin R. Lewis (22279166)

    Published 2025
    “…In a linear mixed model analysis (LMM), the MBSR + PAP arm evidenced a significantly larger decrease in QIDS-SR-16 score than the MBSR-only arm from baseline to 2-weeks post-intervention (between-groups effect = 4.6, 95% CI [1.51, 7.70]; <i>p</i> = 0.008). …”
    Save to List
    Saved in:
  3. 3
    Study CONSORT diagram.

    Study CONSORT diagram. by Benjamin R. Lewis (22279166)

    Published 2025
    “…In a linear mixed model analysis (LMM), the MBSR + PAP arm evidenced a significantly larger decrease in QIDS-SR-16 score than the MBSR-only arm from baseline to 2-weeks post-intervention (between-groups effect = 4.6, 95% CI [1.51, 7.70]; <i>p</i> = 0.008). …”
    Save to List
    Saved in:
  4. 4
    Table_1_The moderating role of the late positive potential in the link between attachment anxiety and emotion regulation difficulties.DOCX

    Table_1_The moderating role of the late positive potential in the link between attachment anxiety and emotion regulation difficulties.DOCX by Miguel Ramos-Henderson (12530649)

    Published 2024
    Save to List
    Saved in:
  5. 5
    Table1_Adverse event signal mining and severe adverse event influencing factor analysis of Lumateperone based on FAERS database.docx

    Table1_Adverse event signal mining and severe adverse event influencing factor analysis of Lumateperone based on FAERS database.docx by Yanjing Zhang (401134)

    Published 2024
    “…</p>Methods<p>AE reports in the FDA Adverse Event Reporting System (FAERS) from 2019 Q4 (FDA approval of Lumateperone) to 2024 Q1 were collected and analyzed. …”
    Save to List
    Saved in:
  6. 6
    Image 4_Effects of gender affirming hormone therapy with testosterone on renal function of assigned female at birth transgender people: a meta-analysis.tif

    Image 4_Effects of gender affirming hormone therapy with testosterone on renal function of assigned female at birth transgender people: a meta-analysis.tif by Daniele Tienforti (11665717)

    Published 2025
    “…When the CKD-EPI equation was referred to the perceived (male) gender, eGFR significantly decreased after 12 months but not after 6 months of T-GAHT. …”
    Save to List
    Saved in:
  7. 7
    Image 3_Effects of gender affirming hormone therapy with testosterone on renal function of assigned female at birth transgender people: a meta-analysis.tif

    Image 3_Effects of gender affirming hormone therapy with testosterone on renal function of assigned female at birth transgender people: a meta-analysis.tif by Daniele Tienforti (11665717)

    Published 2025
    “…When the CKD-EPI equation was referred to the perceived (male) gender, eGFR significantly decreased after 12 months but not after 6 months of T-GAHT. …”
    Save to List
    Saved in:
  8. 8
    Image 1_Effects of gender affirming hormone therapy with testosterone on renal function of assigned female at birth transgender people: a meta-analysis.tif

    Image 1_Effects of gender affirming hormone therapy with testosterone on renal function of assigned female at birth transgender people: a meta-analysis.tif by Daniele Tienforti (11665717)

    Published 2025
    “…When the CKD-EPI equation was referred to the perceived (male) gender, eGFR significantly decreased after 12 months but not after 6 months of T-GAHT. …”
    Save to List
    Saved in:
  9. 9
    Image 2_Effects of gender affirming hormone therapy with testosterone on renal function of assigned female at birth transgender people: a meta-analysis.tif

    Image 2_Effects of gender affirming hormone therapy with testosterone on renal function of assigned female at birth transgender people: a meta-analysis.tif by Daniele Tienforti (11665717)

    Published 2025
    “…When the CKD-EPI equation was referred to the perceived (male) gender, eGFR significantly decreased after 12 months but not after 6 months of T-GAHT. …”
    Save to List
    Saved in:
  10. 10
    Image 5_Effects of gender affirming hormone therapy with testosterone on renal function of assigned female at birth transgender people: a meta-analysis.tif

    Image 5_Effects of gender affirming hormone therapy with testosterone on renal function of assigned female at birth transgender people: a meta-analysis.tif by Daniele Tienforti (11665717)

    Published 2025
    “…When the CKD-EPI equation was referred to the perceived (male) gender, eGFR significantly decreased after 12 months but not after 6 months of T-GAHT. …”
    Save to List
    Saved in:
  11. 11
    Table1_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.docx

    Table1_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.docx by Qiong Jie (13270095)

    Published 2024
    “…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …”
    Save to List
    Saved in:
  12. 12
    Image2_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.TIF

    Image2_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.TIF by Qiong Jie (13270095)

    Published 2024
    “…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …”
    Save to List
    Saved in:
  13. 13
    Table2_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.docx

    Table2_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.docx by Qiong Jie (13270095)

    Published 2024
    “…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …”
    Save to List
    Saved in:
  14. 14
    Image1_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.TIF

    Image1_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.TIF by Qiong Jie (13270095)

    Published 2024
    “…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …”
    Save to List
    Saved in:
  15. 15
    Image 4_Prediction of major adverse cardiovascular events following ST-segment elevation myocardial infarction using cardiac obesity marker—epicardial adipose tissue mass index: a prospective cohort study.tif

    Image 4_Prediction of major adverse cardiovascular events following ST-segment elevation myocardial infarction using cardiac obesity marker—epicardial adipose tissue mass index: a... by Zeyan Liu (3748747)

    Published 2025
    “…Background<p>Although reperfusion therapy has led to improvements in the acute phase of ST-segment elevation myocardial infarction (STEMI), the incidence of major adverse cardiovascular events (MACE) following STEMI has not significantly decreased. …”
    Save to List
    Saved in:
  16. 16
    Image 2_Prediction of major adverse cardiovascular events following ST-segment elevation myocardial infarction using cardiac obesity marker—epicardial adipose tissue mass index: a prospective cohort study.tif

    Image 2_Prediction of major adverse cardiovascular events following ST-segment elevation myocardial infarction using cardiac obesity marker—epicardial adipose tissue mass index: a... by Zeyan Liu (3748747)

    Published 2025
    “…Background<p>Although reperfusion therapy has led to improvements in the acute phase of ST-segment elevation myocardial infarction (STEMI), the incidence of major adverse cardiovascular events (MACE) following STEMI has not significantly decreased. …”
    Save to List
    Saved in:
  17. 17
    Image 5_Prediction of major adverse cardiovascular events following ST-segment elevation myocardial infarction using cardiac obesity marker—epicardial adipose tissue mass index: a prospective cohort study.tif

    Image 5_Prediction of major adverse cardiovascular events following ST-segment elevation myocardial infarction using cardiac obesity marker—epicardial adipose tissue mass index: a... by Zeyan Liu (3748747)

    Published 2025
    “…Background<p>Although reperfusion therapy has led to improvements in the acute phase of ST-segment elevation myocardial infarction (STEMI), the incidence of major adverse cardiovascular events (MACE) following STEMI has not significantly decreased. …”
    Save to List
    Saved in:
  18. 18
    Image 1_Prediction of major adverse cardiovascular events following ST-segment elevation myocardial infarction using cardiac obesity marker—epicardial adipose tissue mass index: a prospective cohort study.tif

    Image 1_Prediction of major adverse cardiovascular events following ST-segment elevation myocardial infarction using cardiac obesity marker—epicardial adipose tissue mass index: a... by Zeyan Liu (3748747)

    Published 2025
    “…Background<p>Although reperfusion therapy has led to improvements in the acute phase of ST-segment elevation myocardial infarction (STEMI), the incidence of major adverse cardiovascular events (MACE) following STEMI has not significantly decreased. …”
    Save to List
    Saved in:
  19. 19
    Image 3_Prediction of major adverse cardiovascular events following ST-segment elevation myocardial infarction using cardiac obesity marker—epicardial adipose tissue mass index: a prospective cohort study.tif

    Image 3_Prediction of major adverse cardiovascular events following ST-segment elevation myocardial infarction using cardiac obesity marker—epicardial adipose tissue mass index: a... by Zeyan Liu (3748747)

    Published 2025
    “…Background<p>Although reperfusion therapy has led to improvements in the acute phase of ST-segment elevation myocardial infarction (STEMI), the incidence of major adverse cardiovascular events (MACE) following STEMI has not significantly decreased. …”
    Save to List
    Saved in:
  20. 20
    Supplementary file 1_Global burden and trends of adverse effects of medical treatment, 1990–2021: an analysis from the global burden of disease study 2021.docx

    Supplementary file 1_Global burden and trends of adverse effects of medical treatment, 1990–2021: an analysis from the global burden of disease study 2021.docx by Keqing Zhang (326894)

    Published 2025
    “…Background<p>Adverse effects of medical treatment (AEMT) pose a significant global health concern, yet prior studies have mostly focused on specific adverse events or single countries, leaving the long-term global epidemiological patterns insufficiently characterized. …”
    Save to List
    Saved in:

Search Tools: